Af­ter sev­er­al high pro­file start­up launch­es, om­niv­o­rous Omega Funds clos­es $438M fund to pur­sue more deals

Omega Funds likes to work back­wards. It in­vests with the end game — de­not­ed by the Greek let­ter in its name — in mind, and it keeps tabs on the num­ber of mar­ket­ed med­ical prod­ucts that cul­mi­nate from its ven­tures: 37 in 16 years.

So when founder and man­ag­ing di­rec­tor Otel­lo Stam­pac­chia de­clares it’s the most ex­cit­ing time to be in­vest­ing in life sci­ences in a gen­er­a­tion, it’s per­haps on­ly nat­ur­al that Omega has closed its largest fund to date. With $438 mil­lion in to­tal com­mit­ments for Fund VI, the firm will con­tin­ue in­ject­ing cap­i­tal in­to a broad swath of com­pa­nies across the US and Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER